MEI PharmaMEIP 
-2.87%24h
MEI Pharma (MEIP) Stock Overview
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
MEIP Stock Information
MEI Pharma (MEIP) Price Chart
MEI Pharma Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $3.05 | N/A |
| Market Cap | $20.32M | N/A |
| Shares Outstanding | 6.66M | 7.05% |
| Employees | 46.00 | N/A |
| Shareholder Equity | 24.62M | -53.02% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.64 | N/A |
| P/S Ratio | 0.42 | N/A |
| P/B Ratio | 0.83 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -1.2930 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $48.82M | N/A |
| Earnings | -$31.84M | N/A |
| EPS | -4.78 | N/A |
| Earnings Yield | -1.57 | N/A |
| Operating Margin | -0.7531 | N/A |
| Net income margin | -0.6522 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $120.81M | N/A |
| Total Debt | $12.73M | N/A |
| Cash on Hand | $100.69M | N/A |
| Debt to Equity | $3.91 | 63.23% |
| Cash to Debt | $7.91 | -50.23% |
| Current Ratio | $5.29 | -22.68% |
